Homology Medicines Reports First Quarter 2019 Financial Results and Recent Highlights
May 13, 2019 16:15 ET
|
Homology Medicines, Inc.
- Received FDA Clearance for IND and Anticipate Starting Phase 1/2 pheNIX Trial for PKU Gene Therapy Candidate with Initial Data Expected by Year End - - Began IND-Enabling Studies for Two Additional...
Homology Medicines to Present at Bank of America Merrill Lynch Health Care Conference
May 09, 2019 08:30 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate during a fireside chat...
Homology Medicines Presents Data from Gene Therapy and Gene Editing Programs and Manufacturing Capabilities at ASGCT Meeting
May 02, 2019 08:00 ET
|
Homology Medicines, Inc.
- Homology’s Scalable HEK293 Suspension Manufacturing Process for AAVHSCs Demonstrated Superiority to a Baculovirus System and AAVHSC15 Showed Improved In Vivo Efficacy Compared to AAV5 in PKU Model -...
Homology Medicines Presents Data Demonstrating Suite of Novel AAV Vectors Targeted Key Cell Types for Inherited Retinal Diseases
April 30, 2019 12:00 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of preclinical data demonstrating that, with...
Homology Medicines Announces Upcoming Presentations on its Gene Therapy and Gene Editing Platform and Manufacturing Capabilities at the American Society of Gene & Cell Therapy Meeting
April 15, 2019 13:05 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today upcoming presentations highlighting its gene therapy and...
Homology Medicines Announces Pricing of Public Offering of Common Stock
April 09, 2019 19:08 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., April 09, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, today announced the pricing of an underwritten public offering of 5,555,556...
Homology Medicines Announces Proposed Public Offering of Common Stock
April 08, 2019 16:10 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, today announced that it intends to offer and sell, subject to market and...
Homology Medicines Presents Preclinical Data from PKU Gene Therapy Program Demonstrating Restored Metabolic Pathway and Increased Neurotransmitter Production
April 04, 2019 16:05 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today preclinical data demonstrating that HMI-102, its gene therapy...
Homology Medicines Announces FDA Clearance of Investigational New Drug Application for HMI-102 Gene Therapy Candidate for PKU
April 04, 2019 07:00 ET
|
Homology Medicines, Inc.
- Phase 1/2 pheNIX Trial Would Represent First PKU Gene Therapy to Enter the Clinic - - Initial Clinical Data Expected by the End of 2019 - BEDFORD, Mass., April 04, 2019 (GLOBE NEWSWIRE) --...
Homology Medicines to Present at the Alliance for Regenerative Medicine Investor Day
March 19, 2019 08:39 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will present during a fireside chat...